医学
杜皮鲁玛
银屑病
特应性皮炎
皮肤病科
队列研究
队列
危险系数
入射(几何)
相对风险
回顾性队列研究
内科学
前瞻性队列研究
免疫学
塞库金单抗
过敏
比例危险模型
免疫失调
需要伤害的数量
贾纳斯激酶
Janus激酶抑制剂
肿瘤科
低风险
安全概况
卫生假说
作者
Brandon R. Block,Jaanvi Mehta,Alice Tang,Benjamin Ungar,Nicholas Gulati
摘要
Dupilumab treatment for atopic dermatitis (AD) has been linked to incident psoriasis, possibly reflecting a T helper 2 (Th2) to Th17 immune shift, but its risk relative to alternative contemporary AD-directed therapies is unclear. To address this question, we performed parallel retrospective cohort studies using the TriNetX Global Collaborative Network and Epic Cosmos. In TriNetX, propensity score-matched dupilumab cohorts were compared with topical corticosteroids (TCS), alternative anti-Th2 biologics (nemolizumab, lebrikizumab, tralokinumab) or Janus kinase (JAK) inhibitors (abrocitinib, upadacitinib), with two-year incident psoriasis assessed via Cox hazard ratios (HRs). Cosmos' larger patient pool permitted an exploratory analysis with agent-level comparisons, evaluating relative risk (RR) of incident psoriasis within a 17-month span. Dupilumab was not associated with increased two-year psoriasis risk versus TCS (HR 0.91, 95% CI 0.77-1.08), alternative anti-Th2 biologics (HR 1.03, 0.49-2.14) or JAK inhibitors (HR 0.86, 0.48-1.51). The data from Cosmos were in line with these findings, with equivalent or lower incidence with dupilumab relative to alternative agents. These data do not support a dupilumab-specific risk of incident psoriasis and may instead reflect diagnostic ambiguity and/or genetic susceptibility to systemic immune shifts; nevertheless, these proposed explanations require confirmation in prospective studies incorporating clinical, histopathologic and genetic data.
科研通智能强力驱动
Strongly Powered by AbleSci AI